Van ECK Associates Corp Acquires 1,010 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Van ECK Associates Corp boosted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 102.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,997 shares of the company’s stock after acquiring an additional 1,010 shares during the period. Van ECK Associates Corp’s holdings in TransMedics Group were worth $125,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Principal Financial Group Inc. grew its stake in TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after buying an additional 146,115 shares during the last quarter. Public Sector Pension Investment Board acquired a new stake in shares of TransMedics Group during the third quarter worth $11,079,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of TransMedics Group by 665.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock worth $11,716,000 after acquiring an additional 64,872 shares during the period. Vaughan Nelson Investment Management L.P. grew its position in TransMedics Group by 24.3% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after purchasing an additional 64,360 shares in the last quarter. Finally, WCM Investment Management LLC bought a new position in shares of TransMedics Group in the 3rd quarter valued at about $8,720,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Buying and Selling at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 7.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TMDX. Oppenheimer restated an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research report on Tuesday, December 3rd. TD Cowen dropped their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Robert W. Baird dropped their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Canaccord Genuity Group dropped their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Finally, Piper Sandler dropped their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Price Performance

NASDAQ TMDX opened at $71.95 on Monday. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37. The firm has a market capitalization of $2.41 billion, a P/E ratio of 76.54 and a beta of 2.12. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The company has a 50-day moving average price of $66.63 and a 200-day moving average price of $104.16.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.